


Amendments to the Claims

Without prejudice or disclaimer, this listing of claims will replace all prior versions and listing of claims in this application.

1. (Original) A compound of the formula



wherein

R^1 is -H, -OH, -O(C₁-C₄ alkyl), -OCOC₆H₅, -OCO(C₁-C₆ alkyl), or -OSO₂(C₂-C₆ alkyl);

R^0 , R^2 and R^3 are each independently -H, -OH, -O(C₁-C₄ alkyl), -OCOC₆H₅, -OCO(C₁-C₆ alkyl), -OSO₂(C₂-C₆ alkyl) or halo;

R^4 is 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, diisopropylamino, or 1-hexamethyleneimino;

n is 2 or 3;


X is -S- or -HC=CH-; and

Y is -O-, -S-, -NH-, -NMe-, or -CH₂-;

or a pharmaceutically acceptable salt thereof.

4

2. (Original) A compound of the formula



wherein

R^1 is -H, -OH, -O(C₁-C₄ alkyl), -OCOC₆H₅, -OCO(C₁-C₆ alkyl), or -OSO₂(C₂-C₆ alkyl);

R^2 and R^3 are each independently -H, -OH, -O(C₁-C₄ alkyl), -OCOC₆H₅, -OCO(C₁-C₆ alkyl), -OSO₂(C₂-C₆ alkyl) or halo;

R^4 is 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, diisopropylamino, or 1-hexamethyleneimino;

n is 2 or 3;

X is -S- or -HC=CH-; and

Y is -O-, -S-, -NH-, -NMe-, or -CH₂-;

or a pharmaceutically acceptable salt thereof.


3. (Presently Amended) A compound according to ~~Claims 1 or 2~~ **Claim 2** wherein Y is -O-.
4. (Presently Amended) A compound according to ~~any one of Claims 1 to 3~~ **Claim 3** wherein n is 2.
5. (Presently Amended) A compound according to ~~any one of Claims 1 to 3~~ **Claim 4** wherein R^1 is -OH or -OCH₃.
6. (Presently Amended) A compound according to ~~any one of Claims 1 to 3~~ **Claim 5** wherein R^1 is -OH.

7. (Presently Amended) A compound according to ~~any one of Claims 1 to 3~~ **Claim 6** wherein R⁴ is 1-piperidinyl or 1-pyrrolidinyl.
8. (Presently Amended) A compound according to ~~any one of Claims 1 to 3~~ **Claim 7** wherein R⁴ is 1-piperidinyl.
9. (Presently Amended) A compound according to ~~any one of Claims 1 to 3~~ **Claim 8** wherein one of R² and R³ is -H.
10. (Presently Amended) A compound according to ~~any one of Claims 1 to 3~~ **Claim 8** wherein one of R² and R³ is -H and the other is -OH.
11. (Presently Amended) A compound according to ~~any one of Claims 1 to 3~~ **Claim 9** wherein both R² and R³ are -H.
12. (Presently Amended) A compound according to ~~any one of Claims 1 to 3~~ **Claim 11** wherein X is -S-.
13. (Presently Amended) A compound according to ~~any one of Claims 1 to 3~~ **Claim 11** wherein X is -HC=CH-.
14. Cancelled
15. (Original) A compound according to Claim 1 wherein said compound is 12-[4-(2-Piperidin-1-yl-ethoxy)-phenyl]-7,12-dihydro-benzo[a]anthracene-3,9-diol or a pharmaceutically acceptable salt thereof.

16. (Presently Amended) A pharmaceutical composition comprising a compound according to ~~any one of Claims 1 to 15~~ **Claim 15**, or a pharmaceutically acceptable salt thereof, ~~and optionally an effective amount of estrogen and progestin,~~ in combination with a pharmaceutically acceptable salt, **carrier,** diluent, or excipient.

17-39 Presently Cancelled

Respectfully submitted,

A handwritten signature in black ink, appearing to read "G. T. Voy".

Gilbert T. Voy
Attorney for Applicant
Registration No. 43,972
Phone: 317-276-2966

Eli Lilly and Company
Patent Division/GTV
Lilly Corporate Center
Indianapolis, Indiana 46285

March 11, 2005